| Literature DB >> 26040515 |
Yang Qian1, Zhao-Chong Zeng2, Yuan Ji3, Yin-Ping Xiao4.
Abstract
OBJECTIVES: This study evaluates the microscopic characteristics of liver metastases from colorectal cancer (LMCRC) invasion and provides a reference for expansion from gross tumor volume (GTV) to clinical targeting volume (CTV).Entities:
Mesh:
Substances:
Year: 2015 PMID: 26040515 PMCID: PMC4462112 DOI: 10.1186/s13014-015-0428-2
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Fig. 1Survey of observations of liver microinvasion from colorectal tumor metastases. a Tumor with a capsule (black cross) and showing a distinct boundary. b Tumor and microinvasions (black arrows) with capsules. c Tumor and microinvasions without capsules. d Tumor with a capsule that does not exhibit microinvasions. e Irregularly protruding microinvasions. f Multiple microinvasions (black arrows) with different sizes and shapes that show obscure boundaries
Fig. 2Liver metastasis (white arrow) of preoperative magnetic resonance images. a T1-w GE. b T1-w arterial enhanced. c T1-w venous enhanced. d T2-w
Factors associated with the presence of microextension
| Clinicopathological factor |
| Microextension, |
|
| |
|---|---|---|---|---|---|
| Absent | Present | ||||
| Sex | 0.790 | 0.598 | |||
| Male | 75 | 28 (37.3 %) | 47 (62.7 %) | ||
| Female | 54 | 20 (37.0 %) | 34 (63.0 %) | ||
| Age | 0.794 | 0.624 | |||
| <65 years | 93 | 34 (36.6 %) | 59 (63.4 %) | ||
| ≥65 years | 36 | 14 (38.9 %) | 22 (61.1 %) | ||
| Synchronous or metachronous | 0.982 | 0.965 | |||
| Synchronous | 70 | 25 (35.7 %) | 45 (64.3 %) | ||
| Metachronous | 59 | 23 (39 %) | 36 (61 %) | ||
| Original site | 3.185 | 0.009 | |||
| Rectum | 48 | 25 (52.1 %) | 23 (47.9 %) | ||
| Colon | 81 | 23 (28.4 %) | 58 (71.6 %) | ||
| Number of tumors | 2.537 | 0.045 | |||
| 1 | 85 | 38 (44.7 %) | 47 (55.3 %) | ||
| >1 | 44 | 10 (22.7 %) | 34 (77.3 %) | ||
| Max tumor diameter | 1.345 | 0.52 | |||
| <3 cm | 39 | 17 (43.6 %) | 22 (56.4 %) | ||
| ≥3 cm | 90 | 31 (34.4 %) | 59 (65.6 %) | ||
| CEA (ng/ml) | 4.805 | 0.001 | |||
| ≤5 | 35 | 20 (57.1 %) | 15 (42.9 %) | ||
| >5 | 94 | 28 (29.8 %) | 66 (70.2 %) | ||
| CA199 (U/ml) | 0.478 | 0.114 | |||
| ≤37 | 68 | 24 (35.3 %) | 44 (64.7 %) | ||
| >37 | 61 | 24 (39.3 %) | 37 (60.7 %) | ||
| Chemotherapy | 0.906 | 0.817 | |||
| Yes | 55 | 21 (38.2 %) | 34 (61.8 %) | ||
| No | 74 | 27 (36.5 %) | 47 (63.5 %) | ||
CEA Carcinoembryonic antigen, CA199 Carbohydrate antigen 19–9
*Determined by binary logistic regression
Fig. 3Cumulative distributions of LMCRC microextensions according to serum CEA level. a Serum CEA levels. b Original primary tumor site. c Intrahepatic tumor number. d A score derived from a combination of these factors
Fig. 4Correlation between tumor sizes measured using magnetic resonance images and pathology specimen slides